Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors

Laura S. Wood, Harvey Lemont, Aminah Jatoi, Mario E. Lacouture, Caroline Robert, Karen Keating, Roger Anderson

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Multikinase inhibitors (MKIs, eg, sorafenib and sunitinib) are oral anticancer agents associated with handfoot skin reaction (HFSR), a cutaneous adverse event affecting 20%-40% of patients treated with these drugs. Although usually mild, symptoms of HFSR can evolve into a painful condition, resulting in a shortened duration or intensity of cancer treatment. An international, interdisciplinary panel of experts recently provided the first consensus recommendations for the management of MKI-associated HFSR.

Original languageEnglish (US)
Pages (from-to)23-29
Number of pages7
JournalCommunity Oncology
Volume7
Issue number1
DOIs
StatePublished - Jan 2010

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors'. Together they form a unique fingerprint.

  • Cite this